Background There is no consensus on how best to define low muscle mass in patients with end-stage renal disease. Use of muscle mass normalized to height-squared has been suggested by geriatric societies but may underestimate sarcopenia, particularly in the setting of excess adiposity. We compared four definitions of low muscle mass in a prevalent hemodialysis cohort.
Introduction
Reduction in skeletal muscle mass with declining muscle strength or function occurs gradually with increasing age and has been called 'sarcopenia'. 1 This process may be more severe among vulnerable populations, such as those with end-stage renal disease (ESRD). In recognition that chronic conditions can contribute to sarcopenia and that loss of strength or function often accompanies muscle wasting, sarcopenia has more recently been defined by both low muscle mass and reduced muscle function. 2 This syndrome is associated with impaired functional capacity, low physical performance, and higher risk of death among communitydwelling elderly individuals. [3] [4] [5] Lower muscle mass, either measured by serum creatinine as a surrogate or by body composition analysis, was independently associated with worse survival in maintenance hemodialysis patients. 6, 7 Additionally, higher lean body mass has been associated with lower mortality risk in a large multi-ethnic ESRD cohort. 8 Expert panels from around the world are in agreement about the importance of sarcopenia and about its general definition, 2,9-11 but there is no consensus regarding operational criteria for sarcopenia. The cut-points to define low muscle mass and the metrics used to normalize muscle mass have varied across studies depending upon the measurement techniques used to assess muscle (whole body vs. appendicular muscle mass) and the data available from reference populations. 12, 13 We and others recently found similar variation across studies among patients with ESRD receiving maintenance hemodialysis. [14] [15] [16] Although skeletal muscle mass indexed to height-squared is a commonly employed metric of relative muscle mass, 17, 18 it has been recognized that normalization by this method may underestimate the prevalence of low muscle mass, particularly in the setting of excess adiposity. 19 Overweight or obese individuals whose muscle mass is low relative to their body size may not be classified as sarcopenic if muscle mass is adjusted only for height. New data in elderly populations show that muscle mass adjusted more generally for body size rather than height alone is more strongly correlated with physical function than muscle mass indexed to height-squared, and some experts have recommend alternative approaches to indexing. 3, 12, 20 Study of the biology of sarcopenia among patients on dialysis and the associations of sarcopenia with disability and death could lead to better treatment options, but different methods of defining low muscle mass have been employed in the dialysis population and have yielded different estimates of the prevalence. 16 Furthermore, previous studies have indicated that the associations between muscle mass and strength among patients on dialysis may differ from associations among healthy individuals. 21, 22 Thus, there is a need to evaluate associations between muscle size and strength in this population in order to determine which measures of muscle size are most closely associated with strength.
In the present study, we used data from a cohort of patients receiving hemodialysis that includes measurements of height, weight, and estimation of muscle mass using bioelectrical impedance spectroscopy (BIS) to compare the prevalence of low muscle mass using muscle mass indexed with height 2 , body weight, body surface area (BSA), and body mass index (BMI), and to examine the relation between low muscle mass according to these distinct methods of normalization and muscle strength and physical performance. We hypothesized that muscle mass normalized to height 2 would classify fewer patients as having low muscle mass, particularly among overweight or obese patients, and would be less strongly correlated with handgrip strength or walking speed in comparison to normalization by body weight and two commonly employed methods of assessing body size. Study coordinators interviewed participants before or during a dialysis session, abstracted recent clinical and laboratory data from medical records, and measured body composition by BIS on the same day prior to the start of the dialysis session. Patients' data were also linked to data from the ESRD Medical Evidence Report (Center for Medicare & Medicaid Services Form 2728) available in the USRDS. ACTIVE/ADIPOSE participants who had data for body composition, muscle strength, and physical performance available (n = 645, 84%) were included in these analyses.
Methods

Study design and participants
Measurements of body composition, muscle mass, strength and physical performance Study coordinators measured height using a stadiometer and recorded weight to the nearest 0.1 kg as the mean of the last three post-dialysis weight measurements in kilogrammes. BSA was derived from the equation 0.007184 × weight (kg) 0.425 × height (cm) 0.725 according to the Du Bois formula. 24 BMI was calculated as weight divided by height in metres squared. The total-body muscle mass was evaluated by multifrequency whole-body BIS, performed before a midweek dialysis session, using a portable device that scans 256 frequencies between 4 and 1000 kHz (SFB7; ImpediMed, San Diego, CA). BIS was measured before dialysis for practical reasons. Predialysis BIS is being used increasingly in clinical practice to guide dialysis fluid removal. 25 Because extracellular water and intracellular water (ICW) can be determined with acceptable precision with multifrequency BIS 26, 27 and our equations to estimate muscle mass distinguish between extracellular water and intracellular water 28 , we felt that predialysis measurements would have acceptable accuracy and would have greater clinical relevance than post-dialysis measures because many dialysis facilities already perform predialysis BIS. Patients were placed in a supine position at least 10 min before measurement. Electrodes were placed in a tetrapolar configuration using the wrist and ankle on the side opposite the dialysis vascular access with proximal and distal electrodes 5 cm apart. Ten consecutive measures were performed within a 1 min period. Total body water was estimated using the resistance extrapolated to infinite frequency. Extracellular water was estimated from resistance extrapolated to zero frequency. The equation for calculation of total-body muscle mass (kg) was 9.52 + 0.331 × whole body BIS-derived intracellular volume (L) + 0.180 × pre-dialysis weight (kg) + 2.77 (if man) -0.113 × age (years). The results of this equation gave a value of R 2 = 0.937 (P < 0.0001) compared with muscle mass from whole-body MRI in a cohort of patients on hemodialysis. 28 Weakness was based on measurement of handgrip strength and assessed on the non-fistula hand before a dialysis session using a hydraulic hand dynamometer (BASELINE®; Fabrication Enterprise, Inc., Irvington, NY, USA). For participants with an indwelling dialysis catheter, we used the dominant hand to test handgrip strength first then repeat the same protocol in the other. Participants were seated at a table with a proper chair height to ensure that their arms could comfortably rest on the table at a right angle with the elbow bent at a 90°angle and shoulder, forearm, and wrist in a neutral position. Forearm and dynamometer were supported by the table top. Participants were instructed to apply as much force as possible to obtain the best performance. Three trials were performed with a 15 s rest period between each trial. The first trial was discarded as a warm up session, and the highest force exerted in the latter two trials was recorded. Participants were asked to walk a marked 15 ft course at a usual pace. Two trials were conducted, and the faster of the two walks was used for analysis. Gait speed was calculated for each participant using distance in metres divided by time to walk the course in seconds.
Definitions of sarcopenia, low muscle strength and low physical performance
The BIS-derived total-body muscle mass was indexed to height 2 , body weight (percentage), BSA, and BMI. Low muscle mass was defined as muscle mass of 2SD or more below sexspecific means of healthy young adults (18-49 years) for each indexing strategy. Reference populations and cutoff points of BIS-derived whole body muscle mass were obtained from the National Health and Nutrition Examination Survey (NHANES) [2003] [2004] 29 using a Stata specific survey command that accounts for the stratified, multistage, probability sampling survey design of NHANES data. Low muscle strength was defined as handgrip strength of less than 26 kg in men and 16 kg in women, and low physical performance was defined as gait speed of less than or equal to 0.8 m/s according to the Foundation for the National Institutes of Health (FNIH) criteria. 30, 31 Statistical analysis Patient characteristics were described using mean ± SD for normally distributed and median (interquartile range) for nonnormally distributed variables. We assessed the correlations between measures using Pearson's correlation (ρ). The prevalence of low muscle mass by different criteria and characteristics of patients included in the analysis were compared between each metric using Student's t-test, Wilcoxon rank sum, or chi-squared tests as appropriate. We used univariable linear regression analyses to study associations among muscle mass and strength or gait speed and logistic regression to assess the extent to which low muscle mass was associated with weak grip and slow gait. We also performed multivariable regression analysis using age, sex, race, and diabetes as covariates. Interactions between low muscle mass and sex, race, and diabetes were tested. Analyses were performed in Stata 13 (StataCorp LP, College Station, TX), and P values less than 0.05 were considered statistically significant.
Results
Patient characteristics and prevalence of low muscle mass
Six hundred forty-five of the 771 ACTIVE/ADIPOSE participants (84%) had data on body composition and were included in these analyses. Patients included in the analysis had shorter dialysis vintage, higher serum creatinine and albumin concentrations, and a lower prevalence of diabetes mellitus (Table S1 ). The average age of participants in the analysed cohort was 56.7 ± 14.5 years; 41.4% of participants were women. Sixty-two percent of participants were black, 23.9% white and 43.9% had diabetes (Table 1) . Median dialysis vintage was 2.8 (1.3-5.4) years. Women had significantly higher BMI than men (29.2 ± 7.6 and 27.4 ± 6.4 kg/m 2 , P = 0.001, respectively). Average percent body fat was 25.5 ± 9.3% in men and 35.9 ± 8.3% in women. The total prevalence of low muscle mass ranged from 8 to 32% depending on the criterion used to standardize total-body muscle mass. Muscle mass indexed to height 2 classified the smallest percentage of patients as having low muscle mass and sarcopenia (low muscle mass combined with low muscle strength), particularly among women, whereas indexing by BSA classified the largest percentage (Table 1) . Men had a statistically significantly higher prevalence of low muscle mass than women when muscle mass was normalized to height 2 and BSA but not body weight or BMI.
Association of low muscle mass with body composition
The association of low muscle mass with BMI and body fat varied according to the definition of low muscle mass ( Table 2 and Figure 1 ). Patients with low muscle mass indexed to height 2 and to BSA had significantly lower BMI than those in the normal muscle mass groups by these criteria (21.1 ± 2.4 vs. 28.8 ± 6.9 kg/m 2 , P < 0.001 for height 2 and 24.3 ± 3.8 vs. 30.0 ± 7.3 kg/m 2 , P < 0.001 for BSA). In contrast, patients who were classified as having low muscle mass by percentage of body weight and muscle mass indexed to BMI had significantly higher BMI than those with normal muscle mass ( Table 2) . Figure 1 shows the distribution of low muscle mass across categories of BMI. Low muscle mass indexed to height 2 was present almost exclusively among normal or underweight patients. Indexing to BSA also showed an inverse association with BMI but did classify a substantial proportion of overweight and some obese patients as having low muscle mass. By contrast, indexing according to body weight and BMI classified more overweight and obese patients than normal or underweight patients as having low muscle mass relative to their size, with the gradient particularly remarkable for the percentage of body weight criterion, by which 55.6% of obese men and 34.3% of obese women had low muscle mass.
Associations between muscle mass, strength, and physical performance
Patients classified with low muscle mass had significantly lower handgrip strength than those with normal muscle mass by all methods except height 2 ( Table 2 ), but the difference was largest according to muscle mass/BMI (À6.84 kg, 95% CI À8.66 to À5.02, P < 0.001).
Handgrip strength was directly and modestly correlated with muscle mass normalized by percentage of body weight, BSA, and BMI (ρ = 0.43, 0.56 and 0.64, P < 0.001, respectively) and less so with muscle mass/height 2 (ρ = 0.31 and P < 0.001) (Figure 2 ). Patients with low muscle mass by all definitions were more likely to be weak than those with normal muscle mass (Table 3 ). However, low muscle mass indexed to height 2 and percentage of body weight were not associated with higher odds of weakness after adjusting for age, sex, race, and diabetes. The association was strongest for muscle mass/BMI, such that patients with low muscle mass/BMI were almost five times more likely to be weak than patients with normal muscle mass/BMI (OR 4.72, 95% CI 3.23 to 6.91; Table 3 ) and this relationship persisted in multivariable logistic regression analysis (OR 1.82, 95% CI 1.13 to 2.94). Sarcopenia among hemodialysis patients 
Sarcopenia among hemodialysis patients
Although the correlation between muscle mass and gait speed was less robust, there were significant direct correlations with muscle mass indexed to percentage of body weight, BSA, and BMI but not with muscle mass indexed to height 2 ( Figure 3 ). Patients classified as having low muscle mass according to all indexing methods had slower walking speed, and low muscle mass was associated with higher odds of slow gait speed for all except the muscle mass/height 2 metric in univariable regression analysis (Table 3) .
Association of muscle mass and performance among subgroups of interest
For most metrics, associations of low muscle mass with strength and gait speed were similar among men and women. However, there were statistically significant interactions between sex and low muscle according to BSA and BMI. Men and women with low muscle mass were significantly weaker than those with normal muscle, but the absolute difference was larger for men. There were no significant interactions based on sex when considering the odds of weak grip strength, which may reflect the different standard cut points for men and women. For diabetes status, there were no significant interactions between association of low muscle mass with muscle strength or gait speed among patients with and without diabetes. Associations between muscle size and strength did not differ significantly among black and non-black patients (Table 4) . However, the association between gait speed and muscle mass did appear to differ according to race and was generally weaker among black patients. These differences were less pronounced after adjusting for other covariates and were no longer statistically significant except for muscle mass/height 2 and muscle mass/body weight when gait speed was considered as a continuous variable.
Discussion
We found that total-body muscle mass normalized to height 2 classified fewer patients as having low muscle mass, Figure 3 Scatter plot between total-body muscle mass indexed to height 2 , percentage of body weight, body surface area, and body mass index and physical performance (gait speed). In our cohort, the prevalence of low muscle mass varied from 8 to 32% with the lowest and highest frequency based on standardization method by height 2 and BSA, respectively. The prevalence of low muscle mass in this study was slightly lower than in a Brazilian cohort 16 that studied elderly patients on maintenance hemodialysis using various methods of estimating muscle mass, including anthropometric measurement, BIS, and dual energy X-ray absorptiometry. In that study, all estimates were indexed to height 2 and compared with norms using NHANES data. They reported the prevalence of low muscle mass measured by BIS was 14%, and the overall prevalence ranged from 4 to 74% depending on the method of body composition assessment and cutpoints applied. In a previous report by Kim and colleagues, 15 the prevalence of low muscle mass using BIS-derived lean tissue mass normalized to BSA in a Korean dialysis cohort was approximately 20% lower than low muscle mass by muscle mass/BSA criteria in ours. These observations are consistent with a systemic review 32 conducted in community-dwelling geriatric populations that highlighted the heterogeneity in prevalence of low muscle mass that arises because of lack of uniformity in the diagnostic criteria, cutpoints, and characteristics of the studied population as well as the choice of reference populations.
Using muscle mass divided by height 2 resulted in a much lower prevalence of low muscle mass compared with other methods, especially among women. Obesity might account for these underestimated results. [33] [34] [35] At equivalent height, individuals with higher body weight and BMI tend to have higher lean body mass. Obese patients who have low muscle mass relative to their body size, termed sarcopenic obesity, might not be identified as having low muscle mass by using normalization to height 2 . A study among healthy individuals also reported that implementation of body weight-adjusted muscle mass criteria resulted in a higher prevalence of sarcopenia and sarcopenic obesity than when height-based criteria were used. 36 Newman et al. 34 proposed the novel concept of using both height and fat mass adjustment to define low muscle mass by a linear regression model-derived residuals method. Although this method may be complicated to use and is not useful for comparing across populations because it inherently relies on data from within the study population rather than normative data, the study did highlight the better performance of metrics that go beyond indexing to height alone.
Total-body muscle mass was more closely related to muscle strength than physical performance (in this case, gait speed), regardless of the method of normalization. Our findings are similar to a previous report in the elderly population that muscle mass was more associated with grip strength than gait speed. 19 In the present study, the likelihood and degree of weakness were associated with low muscle mass by most criteria, but the relation was weakest for muscle mass/height 2 and strongest for the widely used weight adjusted for height indices BMI and BSA (Table 3) . This is in concordance with a study by Estrada et al., 37 which showed that skeletal muscle mass normalized to percentage of body weight was a better predictor of mobility performance than muscle/height 2 in healthy older women. A report from the FNIH sarcopenia project also found that muscle mass indexed to BMI, but not height or weight, was a potential discriminator of weakness. 19 However, whereas muscle/height 2 may underestimate low muscle mass, our data suggest that other methods, particularly muscle as a percentage of body weight, may overestimate low muscle mass among obese patients. On the other hand, low muscle mass by normalization to BSA and BMI, which include both body height and weight, was more closely associated with muscle strength and physical performance, with BMI performing slightly better than BSA and less influenced by race. Similarly, a recent study in the geriatric population concluded that criteria for low muscle mass that adjusted for both height and weight were more associated with weakness as well as poor physical performance than methods using either height or weight alone. 38 Delmonico and colleagues 20 also found that sarcopenia defined by a method adjusting for body fat and height was better at predicting decline in physical function than adjusting for height 2 .
The limitations of this study should be considered. Our cohort was slightly younger and had more black patients than the general US dialysis population. Thus, percentages of patients with low muscle mass in our cohort may not generalize to the whole US population. We did not include a healthy age-matched control group. Thus, although our results are in general agreement with some studies in the general elderly population, 19, 30, 31 we did not directly assess whether these results apply beyond patients on dialysis. We used total muscle mass rather than appendicular lean mass, which may be more closely associated with strength and gait speed. We assessed muscle mass using BIS prior to a dialysis session, which could lead to overestimation of muscle mass (and underestimation of the prevalence of low muscle) in the setting of overhydration 39 , and the lack of gold standard cutpoints of BIS-derived total muscle mass to define low muscle mass should be aware. Nevertheless, whole body muscle mass assessment using BIS is more suitable for routine clinical practice than dual energy X-ray absorptiometry or other techniques because of its simplicity and accessibility. Moreover, the equation for calculating skeletal muscle mass from BIS measurements used in this study was specifically derived from patients receiving hemodialysis (also mid-week, before the dialysis session) and demonstrates an excellent correlation with a gold standard method by magnetic resonance imaging. 28 In conclusion, skeletal muscle mass normalized to heightsquared may underestimate the prevalence of low muscle mass, particularly among overweight and obese patients on hemodialysis. Detection of sarcopenia among obese patients may require adjustment for body size. These results can be used to investigate associations of sarcopenia with outcomes in the dialysis population and to test interventions to address the important problem of sarcopenia.
